14.66
price up icon3.60%   0.51
pre-market  Pre-mercato:  14.86   0.20   +1.36%
loading
Precedente Chiudi:
$14.15
Aprire:
$14.15
Volume 24 ore:
507.35K
Relative Volume:
0.53
Capitalizzazione di mercato:
$595.49M
Reddito:
-
Utile/perdita netta:
$-168.05M
Rapporto P/E:
-2.8577
EPS:
-5.13
Flusso di cassa netto:
$-146.15M
1 W Prestazione:
+0.62%
1M Prestazione:
+0.07%
6M Prestazione:
-74.16%
1 anno Prestazione:
-68.72%
Intervallo 1D:
Value
$14.15
$14.79
Intervallo di 1 settimana:
Value
$13.77
$14.91
Portata 52W:
Value
$9.12
$72.37

Keros Therapeutics Inc Stock (KROS) Company Profile

Name
Nome
Keros Therapeutics Inc
Name
Telefono
617-314-6297
Name
Indirizzo
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Name
Dipendente
163
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-04
Name
Ultimi documenti SEC
Name
KROS's Discussions on Twitter

Confronta KROS con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
KROS
Keros Therapeutics Inc
14.66 582.83M 0 -168.05M -146.15M -5.13
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.93 25.76B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.43 114.53B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.415 40.54M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
84.10 6.44B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.81 65.13B 14.09B 4.50B 2.96B 39.28

Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-01-21 Downgrade Cantor Fitzgerald Overweight → Neutral
2025-01-17 Downgrade Wedbush Outperform → Neutral
2024-12-16 Downgrade Guggenheim Buy → Neutral
2024-12-16 Reiterato Oppenheimer Outperform
2024-12-13 Reiterato H.C. Wainwright Buy
2024-12-12 Downgrade BTIG Research Buy → Neutral
2024-12-12 Downgrade TD Cowen Buy → Hold
2024-12-12 Downgrade William Blair Outperform → Mkt Perform
2024-11-05 Iniziato Jefferies Buy
2024-10-24 Iniziato Cantor Fitzgerald Overweight
2024-10-16 Iniziato Scotiabank Sector Outperform
2024-09-23 Iniziato Guggenheim Buy
2024-06-25 Iniziato Oppenheimer Outperform
2024-02-21 Iniziato William Blair Outperform
2023-12-08 Iniziato Wells Fargo Overweight
2023-07-31 Iniziato Wedbush Outperform
2023-07-26 Iniziato BofA Securities Buy
2023-02-14 Iniziato Cowen Outperform
2022-10-18 Iniziato Truist Buy
2022-07-26 Iniziato BTIG Research Buy
2020-12-08 Reiterato H.C. Wainwright Buy
2020-05-04 Iniziato H.C. Wainwright Buy
2020-05-04 Iniziato Jefferies Buy
2020-05-04 Iniziato Piper Sandler Overweight
2020-05-04 Iniziato SVB Leerink Outperform
Mostra tutto

Keros Therapeutics Inc Borsa (KROS) Ultime notizie

pulisher
Jun 02, 2025

Keros Therapeutics (NASDAQ:KROS) Stock Price Down 3.9%Should You Sell? - MarketBeat

Jun 02, 2025
pulisher
Jun 02, 2025

ProShare Advisors LLC Purchases 2,764 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

Jun 02, 2025
pulisher
Jun 02, 2025

Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by Bank of America Corp DE - Defense World

Jun 02, 2025
pulisher
Jun 01, 2025

D. E. Shaw & Co. Inc. Cuts Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat

Jun 01, 2025
pulisher
Jun 01, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 1,386 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

Jun 01, 2025
pulisher
May 31, 2025

Wedbush Reiterates Neutral Rating for Keros Therapeutics (NASDAQ:KROS) - MarketBeat

May 31, 2025
pulisher
May 31, 2025

Deutsche Bank AG Raises Stake in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

May 31, 2025
pulisher
May 31, 2025

Keros Therapeutics (NASDAQ:KROS) Receives Neutral Rating from Wedbush - Defense World

May 31, 2025
pulisher
May 30, 2025

Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial - MSN

May 30, 2025
pulisher
May 30, 2025

KROS: Wedbush Reiterates Neutral Rating on Keros Therapeutics | - GuruFocus

May 30, 2025
pulisher
May 30, 2025

TFG Asset Management GP Ltd Acquires New Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat

May 30, 2025
pulisher
May 30, 2025

Keros Therapeutics halts PAH drug development, cuts workforce By Investing.com - Investing.com South Africa

May 30, 2025
pulisher
May 29, 2025

Janus Henderson Group PLC Has $226,000 Stake in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat

May 29, 2025
pulisher
May 29, 2025

Shareholders Will Probably Hold Off On Increasing Keros Therapeutics, Inc.'s (NASDAQ:KROS) CEO Compensation For The Time Being - simplywall.st

May 29, 2025
pulisher
May 29, 2025

Keros Therapeutics Shares Drop; Cibotercept Development Halted, Jobs Cut - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

KROS Halts Development of Cibotercept in PAH After Safety Concer - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Keros Therapeutics Announces Corporate Restructuring - citybiz

May 29, 2025
pulisher
May 29, 2025

Keros Therapeutics (KROS) Restructures Focus, Faces Modest Cost Savings | KROS Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45% - Benzinga

May 29, 2025
pulisher
May 29, 2025

Keros stock as mid-stage trial for PAH therapy ends (KROS) - Seeking Alpha

May 29, 2025
pulisher
May 29, 2025

Keros Therapeutics, Inc. Announces Corporate Restructuring - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

Keros Therapeutics Announces Tropos Topline Data And Corporate Restructuring - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

Keros Therapeutics, Inc. Announces TROPOS Topline Data - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

Keros Therapeutics halts PAH drug development, cuts workforce - Investing.com Australia

May 29, 2025
pulisher
May 29, 2025

KROS Announces Workforce Reduction and Strategic Evaluation | KROS Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Keros Therapeutics halts cibotercept development, plans workforce reduction By Investing.com - Investing.com Canada

May 29, 2025
pulisher
May 29, 2025

Keros Therapeutics Discontinues Cibotercept Development in PAH and Announces Corporate Restructuring - Nasdaq

May 29, 2025
pulisher
May 29, 2025

Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring - Yahoo Finance

May 29, 2025
pulisher
May 29, 2025

1 Stock That Turned $1,000 Into $32 Million - The Globe and Mail

May 29, 2025
pulisher
May 29, 2025

Woodline Partners LP Has $6.14 Million Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat

May 29, 2025
pulisher
May 29, 2025

D. E. Shaw & Co. Inc. Sells 174,189 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

May 29, 2025
pulisher
May 28, 2025

Millennium Management LLC Raises Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat

May 28, 2025
pulisher
May 28, 2025

Keros secures Glass Lewis support for director nominees By Investing.com - Investing.com South Africa

May 28, 2025
pulisher
May 27, 2025

BNP Paribas Financial Markets Invests $730,000 in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat

May 27, 2025
pulisher
May 27, 2025

Northern Trust Corp Buys 30,111 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat

May 27, 2025
pulisher
May 27, 2025

Keros secures Glass Lewis support for director nominees - Investing.com Australia

May 27, 2025
pulisher
May 27, 2025

Keros Therapeutics Urges Stockholders to Vote "FOR" Director Nominees Amid Proxy Contest with ADAR1 - Nasdaq

May 27, 2025
pulisher
May 27, 2025

Leading Independent Proxy Advisory Firm Glass Lewis - GlobeNewswire

May 27, 2025
pulisher
May 27, 2025

Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of ... - Bluefield Daily Telegraph

May 27, 2025
pulisher
May 27, 2025

Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Keros’ Director Nominees - GlobeNewswire Inc.

May 27, 2025
pulisher
May 27, 2025

Keros Therapeutics (KROS) Target Price Adjusted by BofA Analyst | KROS Stock News - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Twinbeech Capital LP Raises Stake in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat

May 27, 2025
pulisher
May 26, 2025

(KROS) Trading Signals - news.stocktradersdaily.com

May 26, 2025
pulisher
May 25, 2025

3 Brilliant Stocks to Buy With $200 and Hold for 5 Years - The Globe and Mail

May 25, 2025
pulisher
May 25, 2025

Janus Henderson Group PLC Sells 77,803 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

May 25, 2025
pulisher
May 23, 2025

TFG Asset Management GP Ltd Acquires Shares of 103,000 Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat

May 23, 2025
pulisher
May 23, 2025

Tema Etfs LLC Makes New $565,000 Investment in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat

May 23, 2025
pulisher
May 22, 2025

Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $37.00 Average Target Price from Analysts - MarketBeat

May 22, 2025
pulisher
May 22, 2025

Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Purchased by The Manufacturers Life Insurance Company - MarketBeat

May 22, 2025
pulisher
May 22, 2025

Northern Trust Corp Increases Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

May 22, 2025

Keros Therapeutics Inc Azioni (KROS) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$1.15
price up icon 6.48%
$31.19
price up icon 3.48%
$584.61
price up icon 1.98%
$306.09
price up icon 0.50%
$4.5994
price up icon 2.21%
$490.81
price up icon 0.11%
Capitalizzazione:     |  Volume (24 ore):